TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9759942

Group type: EXPERIMENTAL
Intervention: Ranitidine effervescent formulation
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ranitidine standard formulation
Number of subjects: 98
Study: 7995270

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other ACE inhibitors
Number of subjects: 0
Study: 2899582

Group type: EXPERIMENTAL
Intervention: Detergent containing chlorhexidine (CHX+)
Number of subjects: 2813

Group type: COMPARATOR
Intervention: Detergent without chlorhexidine (CHX-)
Number of subjects: 2813
Study: 30507231

Group type: EXPERIMENTAL
Intervention: Positive message about PBS users
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Negative message about non-PBS users
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study: 27599226

Group type: EXPERIMENTAL
Intervention: Multicomponent engagement package
Number of subjects: 122

Group type: COMPARATOR
Intervention: Brochure plus nonengagement survey interview
Number of subjects: 122
Study: 24479853

Group type: EXPERIMENTAL
Intervention: Leisure education program (intervention)
Number of subjects: 60
Study: 22282300

Group type: EXPERIMENTAL
Intervention: Milk with 250 mg calcium daily
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Soymilk with 250 mg calcium daily
Number of subjects: 141

Group type: COMPARATOR
Intervention: Neither milk nor soymilk (Control)
Number of subjects: 141
Study: 20627524

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal cooling for 1h
Number of subjects: 84
Study: 18355422

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg plus 20 mL antacid suspension taken simultaneously
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg plus 20 mL antacid suspension taken 2 h after rosuvastatin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg alone
Number of subjects: 14
Study: 16155164

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (CE MRA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 40
Study: 12848771

Group type: EXPERIMENTAL
Intervention: 60 mg pseudoephedrine hydrochloride
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10574493

Group type: EXPERIMENTAL
Intervention: Vitreon left intravitreally for 4 weeks (Group B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Vitreon removed at the end of operation (Group A)
Number of subjects: 105
Study: 8690562

Group type: EXPERIMENTAL
Intervention: rhDNase therapy
Number of subjects: 0
Study: 1934252

Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus cytarabine (3‐plus 7‐day schedule for induction, 2‐plus 5‐day schedule for post-induction)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Daunorubicin plus cytarabine (control arm)
Number of subjects: 44
Study: 31082916

Group type: EXPERIMENTAL
Intervention: Surgical resection of the primary tumor followed by systemic therapy (Arm A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Primary systemic therapy (Arm B)
Number of subjects: 90
Study: 30027600

Group type: EXPERIMENTAL
Intervention: Universal test and treat strategy (UTT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-migrants and out-migrants
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV seroconversions
Number of subjects: 0
Study: 29231360

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine (needle‐medicine group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture alone (acupuncture group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medicine alone (medicine group)
Number of subjects: 90
Study: 25045910

Group type: EXPERIMENTAL
Intervention: BCT plus 12-step-oriented IBT
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: BCT
Number of subjects: 105

Group type: COMPARATOR
Intervention: BCT and IBT
Number of subjects: 105
Study: 22050786

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg + Metformin 1000 mg b.i.d.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg + Metformin 500 mg b.i.d.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg b.i.d.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg b.i.d.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg q.d.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combination therapy (Sitagliptin + Metformin)
Number of subjects: 104
Study: 20646032

Group type: EXPERIMENTAL
Intervention: Mandatory comprehensive educational project on disability
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1509
Study: 17557987

Group type: EXPERIMENTAL
Intervention: Aerobic exercise, 60 min/d, 6 days/wk
Number of subjects: 202
Study: 15149480

Group type: EXPERIMENTAL
Intervention: Linkage intervention (details not specified)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Health insurance during follow-up
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Support for abstinence by family or friends
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Recent visit to a medical clinic or physician
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Recent mental health or addictions treatment utilization
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Health status
Number of subjects: 400
Study: 12068843

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 17000

Group type: EXPERIMENTAL
Intervention: Tenecteplase + enoxaparin
Number of subjects: 17000

Group type: COMPARATOR
Intervention: Alteplase + enoxaparin
Number of subjects: 17000

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 17000
Study: 9585285

Group type: EXPERIMENTAL
Intervention: Oral clonidine (3 microg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral temazepam (10-20 mg)
Number of subjects: 50
Study: 9098247

Group type: EXPERIMENTAL
Intervention: Cataract surgery in both eyes
Number of subjects: 772

Group type: COMPARATOR
Intervention: Cataract surgery in one eye
Number of subjects: 772
Study: 2614821

Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Simple instructions (Control)
Number of subjects: 36
Study: 405730

Group type: EXPERIMENTAL
Intervention: 10 mg sodium aurothiomalate weekly
Number of subjects: 60

Group type: COMPARATOR
Intervention: 50 mg sodium aurothiomalate weekly
Number of subjects: 60
Study: 31390330

Group type: EXPERIMENTAL
Intervention: Expiratory flow accelerator (EFA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bubble‐PEP (BP)
Number of subjects: 20
Study: 28159194

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 429

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Prasugrel (after clopidogrel)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Clopidogrel (maintenance)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Thienopyridine-naïve patients loaded with prasugrel
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Overall treatment of HTPR patients
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Overall clinical outcomes
Number of subjects: 429
Study: 25747308

Group type: EXPERIMENTAL
Intervention: Lactation support intervention (met with an International Board‐Certified Lactation Consultant in hospital and 1‐3 times post discharge)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard care for jaundice (control group)
Number of subjects: 99
Study: 23104974

Group type: EXPERIMENTAL
Intervention: Biweekly team meetings through video or phone conferencing
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual care from the hospice
Number of subjects: 249
Study: 21699697

Group type: EXPERIMENTAL
Intervention: CQ40 (extended five-day treatment at 40 mg/kg)
Number of subjects: 142

Group type: COMPARATOR
Intervention: CQ25 (standard three-day treatment at 25 mg/kg)
Number of subjects: 142
Study: 19196886

Group type: EXPERIMENTAL
Intervention: Tadalafil (10 mg o.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ramipril plus Tadalafil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 18
Study: 16234834

Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented formula (33.5 mg/l)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control formula (10 mg/l NT)
Number of subjects: 220
Study: 15144934

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study: 11419885

Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CA)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Exercise Treadmill Testing (ETT)
Number of subjects: 248
Study: 9321530

Group type: EXPERIMENTAL
Intervention: cA2 (5 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: cA2 (10 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: cA2 (20 mg/kg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: cA2
Number of subjects: 108
Study: 8404750

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 1.0 g twice daily for 6 weeks, followed by 1.5 g twice daily for 6 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 2 g daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 3 g daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3081918

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.d.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.d.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31432705

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in second-line setting with PD-L1 ≥1% (KEYNOTE-010)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in first-line setting with PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407)
Number of subjects: 5
Study: 30244214

Group type: EXPERIMENTAL
Intervention: Usual ERS plus web-based behavioural support
Number of subjects: 413

Group type: COMPARATOR
Intervention: Usual ERS alone (control)
Number of subjects: 413
Study: 27299709

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily
Number of subjects: 0
Study: 25023807

Group type: EXPERIMENTAL
Intervention: 30% WDGS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 60% WDGS
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0% WDGS (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 30% WDGS vs 60% WDGS
Number of subjects: 24
Study: 22309355

Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose of 12 mg/kg body-weight (group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Teicoplanin loading dose of 6 mg/kg body-weight (group A)
Number of subjects: 23
Study: 20649710

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg, single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clotrimazole (twice daily)
Number of subjects: 0
Study: 18724234

Group type: EXPERIMENTAL
Intervention: Group II (tacrolimus withdrawal)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Group I (control)
Number of subjects: 87
Study: 15668287

Group type: EXPERIMENTAL
Intervention: docetaxel 30 mg/m(2) and irinotecan 60 mg/m(2) (days 1 and 8)
Number of subjects: 130

Group type: COMPARATOR
Intervention: docetaxel 75 mg/m(2) (day 1)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combination arm (docetaxel + irinotecan)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Docetaxel arm
Number of subjects: 130
Study: 12566596

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study: 10708286

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 112

Group type: COMPARATOR
Intervention: Indinavir
Number of subjects: 112
Study: 9205415

Group type: EXPERIMENTAL
Intervention: Brachial arterial recording force at 2, 5 and 10-100% (10% increments) of the brachial arterial force
Number of subjects: 10
Study: 7901680

Group type: EXPERIMENTAL
Intervention: Beta-carotene (mean concentration 0.35 microgram/g in cases)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Beta-carotene (in smokers)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (mean concentration 193 micrograms/g in cases)
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Control group (mean beta-carotene concentration 0.42 microgram/g)
Number of subjects: 1410
Study: 2877593

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.015 + 0.085 mg/kg body weight at a 3 min interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of vecuronium 0.1 mg/kg body weight
Number of subjects: 0
Study: 29340745

Group type: EXPERIMENTAL
Intervention: 6-week warm-up-based ACL injury prevention programme
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 27636144

Group type: EXPERIMENTAL
Intervention: Aprepitant plus palonosetron (0.075 mg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Aprepitant plus ramosetron (0.3 mg)
Number of subjects: 88
Study: 24698672

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg, twice a day)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 189
Study: 23955431

Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine at 10 (11) vp/mL
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine at 10 (10) vp/mL
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine at 10 (10) vp/mL and 10 (11) vp/mL
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine (all doses)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 72
Study: 20846292

Group type: EXPERIMENTAL
Intervention: ACTH-stimulated 21-deoxycortisol (21DF)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone (17OHP)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Quotient [(21DF + 17OHP)/F]
Number of subjects: 106

Group type: COMPARATOR
Intervention: ACTH-stimulated 21DF
Number of subjects: 106

Group type: COMPARATOR
Intervention: 17OHP
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Correlation between 21DF and 17OHP
Number of subjects: 106
Study: 19186342

Group type: EXPERIMENTAL
Intervention: Garcinia mangostana L. pericarp gel (GM gel) applied topically as an adjunct to periodontal treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (scaling and root planing without GM gel application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 0
Study: 16634974

Group type: EXPERIMENTAL
Intervention: High quality day care provided by the Early Years Centre
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other child care secured by participants
Number of subjects: 0
Study: 12870680

Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11077934

Group type: EXPERIMENTAL
Intervention: Initial IL6 level in infants with possible infection
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Initial IL6 level in infants with probable infection
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Initial IL6 level in infants with definite infection
Number of subjects: 255

Group type: COMPARATOR
Intervention: Initial IL6 level in infants without infection
Number of subjects: 255
Study: 8839551

Group type: EXPERIMENTAL
Intervention: LHRH agonist triptorelin (3.75 mg monthly injections)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 135
Study: 30200281

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A therapy (BoNT‐A) combined with intensive rehabilitation (IR)
Number of subjects: 35
Study: 26702123

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (PY)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Low-fat yogurt (LF)
Number of subjects: 89
Study: 24243216

Group type: EXPERIMENTAL
Intervention: Crushed reformulated OxyContin® (ORF) 30mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Crushed original OxyContin® (OC) 30mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Oxycodone powder (Oxy API) 30mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: OC placebo
Number of subjects: 27
Study: 23751252

Group type: EXPERIMENTAL
Intervention: Indigenous ready-to-use therapeutic food (RUTF) in outpatient therapeutic program (OTP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no RUTF)
Number of subjects: 26
Study: 19394603

Group type: EXPERIMENTAL
Intervention: Intraoperative multimodal analgesia (Diclofenac sodium 100 mg suppository and 0.75% Ropivacaine)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 17825128

Group type: EXPERIMENTAL
Intervention: Monthly bisphosphonate therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly bisphosphonate therapy
Number of subjects: 0
Study: 16198878

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.6 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ep/LVIPVpw
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ep/LVIPVpw > 0.74
Number of subjects: 29
Study: 12115982

Group type: EXPERIMENTAL
Intervention: Triggering potential from an abnormal end‐plate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triggering potential not from an abnormal end‐plate
Number of subjects: 0
Study: 9952362

Group type: EXPERIMENTAL
Intervention: Zidovudine combined with HIV hyperimmune immunoglobulin (HIVIG) infusions administered monthly during pregnancy and to the neonate at birth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine and intravenous immunoglobulin (IVIG) without HIV antibody
Number of subjects: 0
Study: 7484310

Group type: EXPERIMENTAL
Intervention: Social support from an ex-smoker who attended the group program
Number of subjects: 3923

Group type: EXPERIMENTAL
Intervention: Social support from a smoker
Number of subjects: 3923
Study: 2407030

Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine (mean daily dose, 52 mg in 2 divided doses)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Metoprolol (mean daily dose, 155 mg in 2 divided doses)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 6110308

Group type: EXPERIMENTAL
Intervention: terbutaline (Bricanyl)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: KWD 2131
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31810058

Group type: EXPERIMENTAL
Intervention: Maximal vertical jump on one leg 3 times with arms folded across the chest prefatigue to postfatigue
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fatigue protocol: standing heel raises on a custom‐built platform until task failure
Number of subjects: 30
Study: 31365398

Group type: EXPERIMENTAL
Intervention: Debrief interview with a patient-caregiver followed by a written reflection.
Number of subjects: 189

Group type: COMPARATOR
Intervention: Written reflection on a memorable patient encounter (Control).
Number of subjects: 189
Study: 24923259

Group type: EXPERIMENTAL
Intervention: ACT (Acceptance and Commitment Therapy)
Number of subjects: 238
Study: 24117556

Group type: EXPERIMENTAL
Intervention: Faculty-guided training (FG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Self-guided training (SG)
Number of subjects: 72
Study: 20855672

Group type: EXPERIMENTAL
Intervention: Long-pulsed 1064-nm Nd:YAG laser treatment
Number of subjects: 19
Study: 20017331

Group type: EXPERIMENTAL
Intervention: TMZ capsule 150 mg/m2 orally on days 1-5 and CCNU placebo 130 mg/m2 on day 1
Number of subjects: 97

Group type: COMPARATOR
Intervention: CCNU capsule 130 mg/m2 orally on day 1 and TMZ placebo 150 mg/m2 on days 1-5
Number of subjects: 97
Study: 16696391

Group type: EXPERIMENTAL
Intervention: Preoperative '3-in-1' Femoral Nerve Block (FNB) using 30 mL of bupivacaine 0.25%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Postoperative '3-in-1' Femoral Nerve Block (FNB) using 30 mL of bupivacaine 0.25%
Number of subjects: 48
Study: 15477703

Group type: EXPERIMENTAL
Intervention: Individualized visual feedback-based balance training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study: 11399957

Group type: EXPERIMENTAL
Intervention: RTV/SQV/d4T
Number of subjects: 175

Group type: COMPARATOR
Intervention: RTV/SQV
Number of subjects: 175
Study: 9244033

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 70
Study: 8101048

Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 26
Study: 3436330

Group type: EXPERIMENTAL
Intervention: Iopamidol (1.5 ml kg‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amidotrizoate (1.5 ml kg‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amidotrizoate (40 ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Iopamidol (40 ml)
Number of subjects: 20
Study: 28721947

Group type: EXPERIMENTAL
Intervention: Anti-scatter grid (current departmental protocol)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: No anti-scatter grid
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: No anti-scatter grid with a 15 cm air-gap
Number of subjects: 70
Study: 26126162

Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (4-mm cap)
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 1113
Study: 23228561

Group type: EXPERIMENTAL
Intervention: Risedronate sodium (35 mg/wk) for 4 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21907152

Group type: EXPERIMENTAL
Intervention: Meditators
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison between meditators and controls
Number of subjects: 16
Study: 18088197

Group type: EXPERIMENTAL
Intervention: Galantamine (16-24 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15942543

Group type: EXPERIMENTAL
Intervention: Health at every size group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Diet group
Number of subjects: 78